Galapagos Reports 96% CR Rate for GLPG5101 in MCL Patients at ASH 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Source: Newsfilter
- Significant Efficacy: In the ATALANTA-1 study, GLPG5101 achieved a 100% objective response rate among 24 treated MCL patients, with 96% attaining complete response, highlighting the therapy's robust efficacy and potential market appeal.
- Rapid Treatment: The vein-to-vein time for GLPG5101 is only 7 days, significantly reducing the dropout rate to 4% and eliminating the need for bridging therapy, thereby enhancing treatment accessibility for more patients.
- Good Safety Profile: Among 24 patients, GLPG5101 demonstrated a favorable safety profile with no Grade ≥ 3 cytokine release syndrome observed and only one case of Grade ≥ 3 neurological adverse events, indicating its safety in clinical applications.
- Strategic Shift: Galapagos intends to wind down its cell therapy activities while continuing clinical studies and considering acquisition proposals, reflecting the company's adaptability and forward-looking strategy during its transformation process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GLPG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GLPG
Wall Street analysts forecast GLPG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLPG is 30.50 USD with a low forecast of 22.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
1 Buy
1 Hold
2 Sell
Hold
Current: 34.100
Low
22.00
Averages
30.50
High
40.00
Current: 34.100
Low
22.00
Averages
30.50
High
40.00
About GLPG
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vistra Corp Acquires Cogentrix Energy for Approximately $4.7 Billion
- Acquisition Announcement: Vistra Corp has announced the acquisition of Cogentrix Energy for approximately $4.7 billion, which will significantly enhance its competitive position in the energy market and expand its renewable energy portfolio.
- Market Reaction: Following the acquisition news, Vistra's stock rose by 4.13%, reflecting investor optimism regarding the company's future growth potential and further solidifying its position in the energy sector.
- Strategic Implications: This acquisition will not only increase Vistra's asset base but also enhance operational efficiency and market share through the integration of Cogentrix's resources and technologies, driving long-term profitability.
- Industry Outlook: Against the backdrop of global energy transition, Vistra's acquisition strategy indicates a commitment to sustainability, which is expected to attract more investor interest in its clean energy initiatives.
Continue Reading
Microchip Technology Raises Q3 FY2026 Sales Guidance to $1.185 Billion
- Sales Guidance Upgrade: Microchip Technology Inc expects third-quarter fiscal 2026 net sales of approximately $1.185 billion, exceeding its prior guidance range of $1.109 billion to $1.149 billion, indicating strong growth potential amid robust market demand.
- Positive Stock Reaction: In after-hours trading, Microchip's shares rose 3.2% to $69.20, reflecting investor optimism regarding the company's improved performance, which may further enhance market interest in its stock.
- Enhanced Market Competitiveness: With the sales guidance upgrade, Microchip solidifies its competitive position in the semiconductor industry, particularly in rapidly evolving technology sectors, attracting more investor attention.
- Upcoming Earnings Report: The company is set to release its earnings report after market close, with analysts expecting earnings of $1.04 per share and revenue of $761.13 million, providing investors with an opportunity to further assess the company's financial health.
Continue Reading